HRT, Blood Clots, and Mental Health: Why the Estrogen Patch May Be Different

Can women with a history of blood clots safely use hormone replacement therapy? What does the estrogen patch have to do with it, and could HRT actually help with anxiety, depression, brain fog, and other mental health symptoms of perimenopause?

These are questions we hear frequently in women’s mental health care.

For years, many women were told that hormone replacement therapy (HRT) was simply “off the table” if they had a history of blood clots or other clotting risk factors. While estrogen-containing hormone therapy does require careful consideration in women at increased risk for venous thromboembolism (VTE), the story is more nuanced than simply estrogen = blood clots.

The route of estrogen administration matters.

For some women, transdermal estradiol, estrogen delivered through the skin with a patch, gel, or spray, may offer a lower-risk approach than oral estrogen because it avoids the liver's first-pass metabolism.

And for women experiencing significant mood, cognitive, sleep, or anxiety symptoms during perimenopause, addressing the underlying hormonal transition may be an important part of a comprehensive mental health treatment plan.

Why Does the Route of Estrogen Matter?

When estrogen is taken orally, it travels through the gastrointestinal tract and then directly to the liver before entering the systemic circulation. This is called first-pass hepatic metabolism.

That concentrated exposure to the liver can affect the production of several proteins involved in blood clotting and inflammation. Oral estrogen can increase certain coagulation factors and other hepatic proteins associated with thrombotic risk.

Transdermal estradiol works differently.

An estrogen patch delivers estradiol through the skin directly into the bloodstream, substantially avoiding first-pass hepatic metabolism.

This difference is clinically important.

The American College of Obstetricians and Gynecologists (ACOG) notes that oral estrogen may have a prothrombotic effect, while transdermal estrogen has little or no effect on several prothrombotic markers. ACOG recommends that clinicians consider the potentially thrombosis-sparing properties of transdermal estrogen when evaluating hormone therapy.

The Endocrine Society similarly notes that the primary advantage of transdermal estrogen is avoiding the first-pass hepatic effect associated with oral estrogen and recommends low-dose transdermal estrogen as preferable for women with increased VTE risk.

In simple terms:

Oral estrogen → gastrointestinal tract → liver → bloodstream

Transdermal estradiol → skin → bloodstream

The second pathway produces much less direct hepatic exposure.

Does Transdermal Estrogen Eliminate the Risk of Blood Clots?

No.

This is an important distinction. Using an estrogen patch does not mean that a woman has zero risk of DVT or pulmonary embolism.

Hormone therapy decisions should consider the woman's:

• Personal history of DVT or pulmonary embolism

• Known thrombophilia

• Family history of clotting disorders

• Age

• Obesity

• Smoking status

• Cardiovascular disease

• Immobility

• Migraine history

• Other medical conditions and medications

VTE risk increases with age and other factors, including obesity, kidney disease, and cardiovascular disease, and that patches, sprays, and rings may pose less VTE risk than oral estrogen.

In other words, a history of clotting does not automatically mean that every form of estrogen carries the same risk.

Instead, the type, dose, route, and individual patient's risk factors matter. Likewise emphasizes individualized hormone therapy decisions based on factors including the type and dose of hormone therapy, route of administration, timing of initiation, and whether a progestogen is used.

For women with a significant personal history of thrombosis or a known clotting disorder, hormone therapy should be considered carefully and may warrant consultation with the woman's gynecologist and/or hematologist.

What Does This Have to Do With Mental Health?

This is where menopause care becomes particularly interesting for psychiatry. Perimenopause isn't simply a reproductive transition.

It is a period of significant hormonal fluctuation that can coincide with the emergence or worsening of:

• Anxiety

• Depression

• Irritability

• Mood swings

• Panic symptoms

• Poor concentration

• Brain fog

• Sleep disruption

• Low motivation

• Emotional sensitivity

• Decreased stress tolerance

• Premenstrual worsening of psychiatric symptoms

Estrogen receptors are widely distributed throughout the brain, and estrogen influences systems involved in mood, cognition, neurotransmitter activity, cerebral blood flow, and neuronal function.

That doesn't mean that every episode of depression or anxiety in a woman over 40 is caused by estrogen deficiency.

But it does mean that the menopausal transition can be biologically relevant to mental health.

Can HRT Improve Depression and Anxiety?

Potentially, but the answer isn't as simple as “estrogen is an antidepressant.”

Research suggests that estrogen may have meaningful effects on mood, particularly during the perimenopausal transition. A recent review found evidence suggesting that transdermal estradiol may have antidepressant effects in some perimenopausal women, although evidence in postmenopausal depression remains less consistent.

Other research has found that the relationship between menopause, hormones, cognition, and mental health is complex. Large randomized trials have not consistently demonstrated that menopausal hormone therapy independently prevents or treats depression in all women.

So we don't recommend thinking about HRT as a replacement for psychiatric treatment.

Instead, we view it as one potential component of an individualized treatment plan.

For the right patient, stabilizing the hormonal environment may complement traditional psychiatric treatment.

What About Brain Fog?

“Brain fog” is one of the most common complaints we hear from women during perimenopause.

Women may describe:

“I can't find the words I'm looking for.”

“I can't remember why I walked into a room.”

“I used to be so organized, and now I can't keep up.”

“My ADHD suddenly feels dramatically worse.”

“I can read something three times and not absorb it.”

These symptoms can be especially frustrating for women who have historically been high functioning.

Hormonal fluctuations may contribute to changes in attention, working memory, sleep, mood, and cognitive processing during the menopausal transition. Estrogen has numerous effects on brain physiology, although the evidence that HRT produces long-term cognitive improvement is still evolving.

This is why a comprehensive evaluation matters.

Brain fog can be related to menopause, but it can also be caused or worsened by:

• ADHD

• Depression

• Anxiety

• Insomnia

• Sleep apnea

• Iron deficiency

• Vitamin B12 deficiency

• Thyroid dysfunction

• Medication side effects

• Chronic stress

• Other medical conditions

A functional psychiatry approach looks at the whole picture rather than assuming every symptom has one cause.

Why We Often Think About Transdermal Estradiol First

When systemic estrogen is appropriate, the delivery method is an important part of the conversation.

Transdermal estradiol allows us to provide systemic estrogen while avoiding the substantial first-pass hepatic exposure associated with oral estrogen.

For women who have metabolic risk factors or increased VTE risk, this distinction can be particularly important. Transdermal routes and lower doses may decrease the risk of VTE and stroke compared with oral therapy. This doesn't mean that every woman should use a patch.

It means that route of administration should be part of the risk-benefit conversation.

What About Progesterone?

Women who still have a uterus generally need endometrial protection when systemic estrogen is prescribed.

That typically means adding a progestogen.

The choice of progestogen matters because different formulations can have different effects on bleeding, mood, breast health, and potentially cardiovascular and thrombotic risk.

Natural micronized progesterone is one option frequently considered in menopausal hormone therapy, although the appropriate choice depends on the individual patient.

This is another reason why HRT shouldn't be viewed as simply: “Take estrogen.”

HRT Isn't Just About Hot Flashes

One of the biggest misconceptions about hormone therapy is that it is only for women experiencing hot flashes.

Menopausal hormone therapy is most established for vasomotor symptoms such as hot flashes and night sweats, as well as genitourinary symptoms of menopause. It also has established benefits for bone health in appropriate patients.

But women often come to psychiatric care because their symptoms are different.

They may say:

“I'm anxious all the time.”

“My depression suddenly feels different.”

“I can't concentrate.”

“I'm exhausted.”

“I don't feel like myself anymore.”

“My ADHD medication isn't working the way it used to.”

“I wake up at 3 a.m. and can't fall back asleep.”

Sometimes the missing piece isn't another psychiatric medication.

Sometimes it is recognizing that the patient's reproductive hormones have changed and that those changes may be interacting with her brain, sleep, stress response, and existing psychiatric vulnerabilities.

A Whole-Person Approach to Women's Mental Health

At a women's health-focused psychiatry practice, we don't believe that every symptom should automatically be blamed on hormones.

We also don't believe that hormones should be ignored when a woman is clearly experiencing a major reproductive transition.

The goal is to understand the interaction between:

Hormones + brain chemistry + sleep + nutrition + stress + psychiatric history + physical health

That may mean optimizing an antidepressant.

It may mean treating ADHD.

It may mean addressing insomnia.

It may mean evaluating thyroid, iron, B12, or vitamin deficiencies.

And for an appropriate patient, it may mean discussing whether menopausal hormone therapy could be part of the treatment plan.

The Bottom Line: Estrogen and Blood Clots Are More Complicated Than You May Think

If you've been told that you can't consider HRT because of a history of blood clots or clotting risk, it may be worth having a more nuanced conversation with a menopause-informed clinician.

Oral estrogen and transdermal estradiol do not have identical effects on the coagulation system.

Transdermal estrogen avoids first-pass hepatic metabolism and appears to have a more favorable VTE profile than oral estrogen, particularly when used at lower doses.

But “lower risk” does not mean “no risk.”

Hormone therapy should always be individualized based on your personal medical history, reproductive status, cardiovascular and clotting risk, symptoms, and treatment goals.

And when you're experiencing significant anxiety, depression, brain fog, sleep changes, or difficulty functioning during perimenopause or menopause, your hormones deserve to be part of the conversation.

Frequently Asked Questions

Can women with a history of blood clots use HRT?

Sometimes, but this requires individualized risk assessment. Transdermal estradiol may have a more favorable clotting profile than oral estrogen, but women with previous DVT/PE or known thrombophilia should discuss hormone therapy with an appropriately qualified clinician and may need hematology input.

Is an estrogen patch safer than oral estrogen for blood clots?

Evidence suggests that transdermal estrogen has less effect on coagulation factors and may carry a lower VTE risk than oral estrogen.

Does an estrogen patch bypass the liver?

It substantially avoids the first-pass hepatic metabolism that occurs when estrogen is taken orally. Estrogen absorbed through the skin enters systemic circulation without first traveling through the gastrointestinal tract and liver.

Can HRT help anxiety during perimenopause?

It may help some women, particularly when mood symptoms occur in the context of the menopausal transition. However, evidence is mixed, and HRT should not automatically replace evidence-based psychiatric treatment.

Can HRT help depression?

Estrogen may have antidepressant effects in some perimenopausal women, but HRT is not a universal treatment for depression. Individual psychiatric history and the severity and type of symptoms should guide treatment.

Can estrogen help brain fog?

Hormonal fluctuations can contribute to cognitive symptoms during perimenopause, but brain fog has many potential causes. Sleep, ADHD, depression, anxiety, nutritional deficiencies, thyroid problems, medications, and other medical conditions should also be considered.

Interested in a More Personalized Approach to Women's Mental Health?

If you're navigating perimenopause or menopause and noticing changes in your mood, anxiety, sleep, attention, or overall sense of well-being, you don't have to choose between “it's all hormones” and “it's all psychiatric.”

There may be value in looking at both.

A women's health-focused psychiatric evaluation can help identify the factors contributing to your symptoms and determine whether psychiatric treatment, lifestyle changes, hormone therapy, or a combination of approaches may be appropriate.

Your hormones are part of your mental health story, but they aren't the whole story.

If you have more questions or would like a comprehensive assessment of your functional and mental status, you can start here thealchemy-institute.com/intake-form